High rate of indigenous bronchiolitis and palivuzumab.
Whitehall
J S
JS
Bolisetty
S
S
Whitehall
J P
JP
Francis
F
F
Norton
R
R
Patole
S K
SK
D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000191:economics / Q000627:therapeutic use*; D001315:Australia; D001990:Bronchiolitis, Viral / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D007223:Infant; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy* / Q000453:epidemiology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab